IMS World Review Executive 2010

TM

20TH ANNIVERSARY EDITION

IMS WORLD REVIEW EXECUTIVE 2010

Preface
IMS World Review ExecutiveTM 2010 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2005 to 2009, including the breakdown of sales by regions, countries, therapeutic areas, products and companies. This handy pocket-size guide will give company executives the opportunity to obtain the most accurate and consistent pharmaceutical sales data available on the market. For its 20th Anniversary, IMS World Review ExecutiveTM has been enhanced to include additional datasets such as insights on Biologics and Generics. The format and layout have also been improved to allow this resource to be recognized as a unique global market overview. IMS World Review ExecutiveTM also provides critical insights into the future which can be found in the new chapter called: Global Pharmaceutical Outlook to 2014. A combination of qualitative insights and top line forecasts allow the reader to understand the prognosis of the global pharmaceutical market. IMS Health 7 Harewood Avenue London NW1 6JB United Kingdom Tel: + 44 203 075 5888 Mail: Service@imshealth.com www.imshealth.com

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions. This Information Service is provided to the Client on a personal basis under a non-exclusive and non-transferable licence for the Clients own direct benefit and use only, and may not be copied or divulged to any other party. Whilst every possible care has been taken in the preparation of this information, the publishers do not hold themselves responsible for any expressions of opinion or error or omission, or any action resulting therefrom. 2010. IMS Health Incorporated or its affiliates. All rights reserved
ii IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

IMS WORLD REVIEW EXECUTIVE 2010

Table of Content
PREFACE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . i WORldWIdE PhARMACEuTICAl MARkETS - ESTIMATEd MARkET Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Market Estimates by Region . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Market Estimates for Top 30 Countries . . . . . . . . . . . . . . . . . . . . . . Market Estimates for Other IMS Audited Countries . . . . . . . . . . . . . . REGIONAl & COuNTRY MARkET TRENdS - AudITEd MARkET . . . Worldwide Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . North America Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . Europe Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Africa, Asia & Australasia Growth Trends . . . . . . . . . . . . . . . . . . . . Latin America Growth Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . Five Year Growth Rates by Country . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ............................ 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 . . . . . . . . . . . . . . . . . . . . . . . . . . . .2 . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 ............................ 9 . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

WORldWIdE PhARMACEuTICAl CORPORATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Top 100 Worldwide Corporations - Worldwide Sales & Regional Market Share . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Fastest Growing 50 Corporations - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 WORldWIdE ThERAPEuTIC AREAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Sub-Therapeutic Classes Analysis - Worldwide Sales & Regional Market Share . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Top 50 Therapeutic Areas (ATC3) - Leading Corporations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Fastest Growing 100 Therapeutic Areas - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . 124

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

iii

IMS WORLD REVIEW EXECUTIVE 2010

Table of Content
WORldWIdE PhARMACEuTICAl PROduCTS . . . . . . . . . . . . . . . . . . Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Top 75 Worldwide Products - Worldwide Sales & Regional Market Share Fastest Growing 80 Products - Five Year Worldwide Sales Trends . . . . . Top 50 New Active Substances - Five Year Worldwide Sales Trends. . . . Top 50 Biologics - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . Top 50 Generic Products - Five Year Worldwide Sales Trends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131 . . . . . . . . . . . . . . . . . . . . . . . . . . . 131 . . . . . . . . . . . . . . . . . . . . . . . . . . . 132 . . . . . . . . . . . . . . . . . . . . . . . . . . . 145 . . . . . . . . . . . . . . . . . . . . . . . . . . . 151 . . . . . . . . . . . . . . . . . . . . . . . . . . . 155 . . . . . . . . . . . . . . . . . . . . . . . . . . . 158

GlOBAl PhARMACEuTICAl OuTlOOk TO 2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167 APPENdICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Estimated Market Universe . . . . . . . . . . . . . . . . . . . . . . . . . . . . Audited Market Universe & Panels . . . . . . . . . . . . . . . . . . . . . . . IMS New Active Substance Definition . . . . . . . . . . . . . . . . . . . . . IMS Generics Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IMS Biologics Definition. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sales Data Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169 . . . . . . . . . . . . . . . . . . . . . . . . . . 169 . . . . . . . . . . . . . . . . . . . . . . . . . . 175 . . . . . . . . . . . . . . . . . . . . . . . . . . 183 . . . . . . . . . . . . . . . . . . . . . . . . . . 185 . . . . . . . . . . . . . . . . . . . . . . . . . . 189 . . . . . . . . . . . . . . . . . . . . . . . . . . 192

CONTACT uS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195

iv

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

WORLDWIDE PHARMACEUTICAL MARKETS - ESTIMATED MARKET

Introduction
This section provides a sales data overview of the 2009 world pharmaceutical markets, using the Estimated Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for all regions as well as for all IMS audited countries, allowing you to understand the performance of each country market and their evolution over the years. To give you as complete a picture as possible, estimated sales through all distribution channels in all countries are shown (Market Estimates by Region), whether these channels are audited by IMS Health or not. These estimates are intended to include both prescription and most non-prescription products. We provide these estimates to put into perspective the information contained in all other sections of IMS World Review Executive, which is based on IMS Health audit information only. For any country audited by IMS Health, the total market estimate is based on the audited figure, with allowances made for non-audited sectors of the market, based on information from IMS Health audits. For non-audited markets we have used the technique of reverse evaluation of export statistics, export statistics of the major exporting countries are matched up with local import statistics. Retained local production is added in, to arrive at a total market estimate. Please refer to the Appendices to review all the countries included in the Estimated Market Universe.

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

WORLDWIDE PHARMACEUTICAL MARKETS - ESTIMATED MARKET

Market Estimates by Region
CHART 1

2009 Country North America Europe Africa, Asia & Australasia Latin America $ (Bill) 319.5 236.7 201.8 48.7

Revised 2008 $ (Bill) 304.1 246.6 179.2 48.4

Revised 2007 $ (Bill) 298.6 217.8 155.1 42.1

Revised 2006 $ (Bill) 285.7 186.3 137.2 35.9

Revised 2005 $ (Bill) 261.1 174.4 133.5 32.2

USD Millions
$319,452 North America 39.7%

$48,654 Latin America 6.0%

TOTAL WORLD MARKET ($ Billion) GROWTH OVER PREVIOUS YEAR (%)

806.6 3.6%

778.3 9.1%

713.6 10.6%

645.0 7.3%

601.2

$236,690 Europe 29.3% $201,795 Africa, Asia & Australasia 25.0%

Worldwide Pharmaceutical Market Estimate 2009 = $806.6 Billion

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

WORLDWIDE PHARMACEUTICAL MARKETS - ESTIMATED MARKET

Market Estimates for Top 30 Countries

2009 Rank Country

2009 $ (Mill)

2009 Growth (%) $ lCd

Revised 2008 $ (Mill)

2008 Growth (%) $ lCd

Revised 2007 $ (Mill)

2007 Growth (%) $ lCd

Revised 2006 $ (Mill)

2006 Growth (%) $ lCd

Revised 2005 $ (Mill)

2005 Growth (%) $ lCd

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

United States Japan Germany France China Italy Spain United Kingdom Canada Brazil Russian Federation India Mexico Turkey South Korea Australia Greece Venezuela Poland Belgium Netherlands

300748 89865 41275 40575 31688 26857 22818 19843 18705 17403 11442 10405 10399 10276 9472 9423 7537 6626 6601 6208 5417

5 17 -2 -5 29 -1 1 -11 -0 4 -9 7 -17 -4 -3 0 4 31 -15 -2 -8

5 6 4 1 27 4 6 5 6 13 15 19 1 16 14 7 10 31 10 3 -3

285285 77041 41932 42526 24545 27169 22620 22234 18786 16749 12609 9725 12576 10660 9756 9388 7254 5050 7794 6356 5914

2 17 12 10 39 12 16 -5 7 22 38 4 0 12 -5 11 18 33 27 14 4

2 3 5 3 27 4 8 3 6 14 35 11 2 12 10 10 10 33 9 6 -4

280995 65730 37278 38495 17698 24234 19563 23368 17590 13708 9118 9314 12525 9508 10287 8443 6124 3793 6160 5565 5712

4 3 16 16 32 15 19 14 13 25 12 25 8 29 14 23 28 33 23 15 16

4 4 6 6 26 6 9 5 6 11 5 13 8 17 11 11 18 33 9 6 7

270108 63711 32076 33217 13441 20989 16486 20505 15549 10957 8132 7463 11598 7363 9049 6843 4772 2862 5022 4822 4909

9 -6 3 4 16 5 9 6 15 13 41 15 5 5 20 3 12 30 9 2 4

9 -1 2 3 13 4 8 4 8 2 35 18 6 12 12 4 11 32 4 2 3

247654 67741 31100 32041 11612 19949 15129 19433 13489 9687 5747 6503 11000 7009 7547 6616 4249 2200 4623 4709 4709

5 5 7 7 22 4 8 -3 15 37 50 12 16 54 27 9 13 18 21 4 3

5 7 8 7 20 4 8 -2 7 13 48 9 12 46 13 5 13 32 8 4 3

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

REGIONAL & COUNTRY MARKET TRENDS - AUDITED MARKET

Introduction
This section provides a sales data overview of the 2009 world pharmaceutical markets, using the IMS Audited Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for all regions. Growth rates based on US$ from 2005 to 2009 are shown for all IMS audited countries, allowing you to understand the performance of each country market and their evolution over the years. IMS Healths pharmaceutical audits for individual countries serve as the main source of comparative sales data on the pharmaceutical industry. The audits are continuous, periodic market surveys based on statistically representative samples, the data from which provide regional and national estimates. In the major countries, the pharmaceutical audits incorporate transaction data from wholesalers giving rise to a near-census of the retail market. Each country audit records the data according to local requirements. Therefore the way data is collected and held will vary from country to country. In the European countries and America, the majority of pharmaceuticals are dispensed or sold mainly through retail pharmacies and drug stores. Thus sampling at the retail pharmacy level in such countries will represent a major proportion of the total market. Consequently, most of the IMS Health audits are sampled through retail pharmacies. There are some exceptions, for example Japan (see Japan section). The audits provide a comprehensive record of purchases of pharmaceuticals in each country. A number of retail pharmacies and wholesalers are chosen for sampling (sample size) and sales data is collected by IMS Health on a regular basis. This data is then projected to estimate sales for the total number of retail pharmacies in a country (this is referred to as the universe). With some variation in each country, the sales estimates shown represent direct and indirect purchases by retail pharmacies from pharmaceutical wholesalers and manufacturers. It should be noted that, whilst IMS Health data is the most comprehensive source available to monitor sales through their retail channels, some products are more widely distributed and used in a hospital or clinic environment (for example oncology, diagnostic or specialist anti-infective treatments). For such products, IMS Health retailer-based audits do not provide comprehensive coverage, and supplementary data sources will be required to project these data to a total universe for these specialist products. The sales data in IMS World Review Executive is calculated based on sales from manufacturer to wholesalers known as the exmanufacturer price.

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

REGIONAL & COUNTRY MARKET TRENDS - AUDITED MARKET

Introduction
In many countries, including USA, Canada, Japan and throughout Latin America, these are estimated weighted average factors, which take into account varying margins and the direct/indirect sales mix. As market conditions change the conversion factors are updated by the local IMS offices. Changes in factors are not retroactively applied to historical data. Data is collected in each country in local currency. This is converted into US Dollars using the prevailing average exchange rate for the quarter. Please refer to the Appendices to review all the countries included in the Audited Market Universe.

10

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

REGIONAL & COUNTRY MARKET TRENDS - AUDITED MARKET

Worldwide Growth Trends

Based on uS$ Worldwide

Growth $ (%) AV Growth **AV Growth 2009 2008 2007 2006 2005 $ (%) $ (%) 3 8 10 7 8 7 7
800000

USD Millions

+10.0%

+7.6%

NORTH AMERICA EUROPE A/A/A LATIN AMERICA

5 -4 12 2

2 12 15 15

5 16 12 17

9 6 2 15

6 8 12 19

5 7 11 13

5 7 11 13

700000
+7.9%

+6.9% +12.3%

600000 500000 400000 300000 200000 100000 0

2005 2006 2007 2008 2009

$567,969 $609,526 $670,422 $726,164 $751,027

2005

2006

2007

2008

2009

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

11

WORLDWIDE PHARMACEUTICAL CORPORATIONS

Introduction
This section provides a sales data overview of the 2009 leading pharmaceutical corporations, using the IMS Audited Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for the top 100 corporations, as well as their market share in North America, Europe, Africa-Australasia-Asia, and Latin America. Please refer to the Appendices - Audited Market Universe and Panels section - to view the countries included in each region. This section also includes the fastest-growing 50 corporations, including US$ sales and growth rates over 2005 to 2009.

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

25

WORLDWIDE THERAPEUTIC AREAS

Introduction
This section provides a sales data overview of the 2009 leading therapeutic areas, using the IMS Audited Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for all therapeutic classes at level 4, as well as their market share in North America, Europe, Africa-Australasia-Asia, and Latin America. Please refer to the Appendices - Audited Market Universe and Panels section - to view the countries included in each region. This section also profiles the top 50 therapeutic areas at level 3, showing the leading 15 corporations. This is complemented by a view of the fastest-growing 100 therapeutic areas, including US$ sales and growth rates over 2005 to 2009.

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

35

WORLDWIDE PHARMACEUTICAL PRODUCTS

Introduction
This section provides a sales data overview of the 2009 leading pharmaceutical products, using the IMS Audited Market Universe. US$ sales values and growth rates from 2005 to 2009 are displayed for the top 75 products, as well as their market share in North America, Europe, Africa-Australasia-Asia, and Latin America. Please refer to the Appendices - Audited Market Universe and Panels section - to view the countries included in each region. This section also includes the fastest-growing 80 Products, including US$ sales and growth rates over 2005 to 2009. Sales data over 2005 to 2009 is also provided for the top 50 New Active Substances, Generics and Biologics. Please refer to the Appendices to understand how IMS defines New Active Substances, Generics and Biologics.

IMS World Review Executive 2010 2010 IMS Health Incorporated or its affiliates. All rights reserved.

131

ABOUT IMS

IMS HEALTH 7 Harewood Avenue London NW1 6JB UK Tel: +44 (0)20 3075 5888 www.imshealth.com

Operating in more than 100 countries, IMS Health is the worlds leading provider of market intelligence to the pharmaceutical and healthcare industries With $2.2 billion in 2009 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products and services that are integral to clients day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com